Twist Bioscience (NASDAQ:TWST) Director Sells $51,000.00 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) Director Melissa Starovasnik sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $51.00, for a total transaction of $51,000.00. Following the completion of the transaction, the director directly owned 25,722 shares in the company, valued at $1,311,822. This represents a 3.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $50.21 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of -39.23 and a beta of 2.20. The firm has a 50-day moving average of $46.99 and a two-hundred day moving average of $37.43. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $57.88.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The company had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The firm’s revenue was up 16.9% compared to the same quarter last year. On average, research analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds have recently made changes to their positions in TWST. Stifel Financial Corp boosted its position in Twist Bioscience by 3.6% during the fourth quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock valued at $246,000 after purchasing an additional 271 shares in the last quarter. D.A. Davidson & CO. raised its holdings in Twist Bioscience by 1.2% in the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after purchasing an additional 305 shares in the last quarter. CWM LLC lifted its position in shares of Twist Bioscience by 9.4% during the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock valued at $150,000 after buying an additional 407 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after buying an additional 442 shares during the last quarter. Finally, California State Teachers Retirement System boosted its holdings in shares of Twist Bioscience by 0.8% in the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock valued at $1,994,000 after buying an additional 442 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on TWST. Evercore upped their target price on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Barclays upped their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 3rd. Guggenheim increased their target price on shares of Twist Bioscience from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Seven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.